Novan, Inc. Stock News

DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ: NOVN ), today announced that data from the Company''s completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as SB206) for molluscum contagiosum will be presented at the 2022 Winter Clinical Dermatology Conference, being held January 14-19, 2022, in Koloa, Hawaii. Berdazimer 10.3% gel, containing new chemical entity berdazimer (sodium), is in late-stage development and poised as a first-in-class topical controlled-nitric oxide releasing medication for the treatment of molluscum contagiosum, a highly contagious viral skin disease affecting an estimated 6 million people in the US, mostly children, if approved. There is currently no US Food & Drug Administration (FDA) approved medication indicated for the treatment of molluscum. If approved, the Company believes berdazimer 10.3% gel would offer those infected with molluscum a potential prescription therapeutic approach that could allow patients and/or caregivers to directly apply treatment gel to molluscum lesions.

European stocks dropped on Monday, with tech companies leading a downward slide on worries about rising interest rates.

Novartis AG and Molecular Partners AG on Monday reported positive topline data from their antiviral Covid-19 treatment ensovibep, and will seek expedited regulatory authorizations globally.

Basel, January 10, 2022 — Novartis and Molecular Partners today announced that Part A of the EMPATHY clinical trial1 that compared single intravenous doses of ensovibep, a DARPin antiviral therapeut

DUBLIN , Jan. 5, 2022 The "Narcolepsy Drugs Market by Disease and Therapeutic Type: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com''s offering. The narcolepsy drugs market was valued at $2,680.06 million in 2020, and is projected to reach $6,667.80 million by 2030, registering a CAGR of 9.6% from 2021 to 2030. Narcolepsy is mainly a long-term neurological disorder characterized by a classic tetrad of excessive daytime sleepiness with irresistible sleep attacks, cataplexy (sudden bilateral loss of muscle tone), hypnagogic hallucination, and sleep paralysis. Around 70% individuals experience episodes of sudden loss of muscle strength, this is often referred to as cataplexy, which can be brought on by strong emotions. Less commonly, there may be inability to move or vivid hallucinations when falling asleep or waking up. People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.

Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No. 9,187,405 covering a dosi

In last trading session, Novan Inc. (NASDAQ:NOVN) saw 0.26 million shares changing hands with its beta currently measuring -0.04. Companys recent per share price level of $4.35 trading at $0.09 or 2.11% at ring of the bell on the day assigns it a market valuation of $81.26M. That closing price of NOVNs stock is at Novan Inc. (NASDAQ:NOVN): Buy, Sell Or Hold At $4.35? Read More »

European equities pushed higher on Thursday, the last full trading day of the week.

Basel, December 22, 2021 — Novartis, a leader in rheumatology and immuno-dermatology, today announced the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatmen

Ad hoc announcement pursuant to Art. 53 LR

Basel, December 22, 2021 — Novartis announced today that it entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope

Basel, December 22, 2021 — Sandoz, a global leader in generic and biosimilar medicines, today announced that it has submitted a Marketing Authorization Application for a proposed biosimilar trastuzu

Basel, December 20, 2021 — Sandoz, a global leader in generic and biosimilar medicines, today announced the submission of its Biologics License Application (BLA) for a proposed biosimilar trastuzuma

The week has started on a down note after a weekend full of headlines over spreading COVID-19 cases and rising restrictions.

Basel, December 20, 2021 — Novartis announced today the signing of an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the company’s research a